Cytochromes are proteins that catalyze electron transfer reactions of well-known metabolic pathways and are classified in various superfamilies. The CYP, or P450, superfamily accounts for 90% of the oxidative metabolism of clinical drugs. One member of this superfamily, P450 2D6 (or CYP2D6), singlehandedly metabolizes about 25% of all medications in the human liver. Cytochrome P450 2D6: Structure, Function, Regulation, and Polymorphism reviews the current knowledge of CYP2D6 as well as the maturing body of evidence indicating its significance to clinical and pharmacological researchers and practitioners.
This book focuses on the critical role CYP2D6 plays in the human liver. It examines the genetic, epigenetic, physiological, pathological, and structural factors of the gene that govern the highly variable metabolism of a number of drugs in clinical use. It highlights the impact of the functional roles of CYP2D6 on clinical practice and drug development and also discusses implications for precise medicine, strategies to avoid adverse drug reactions, and paths for future research.
Cytochrome P450 2D6 is a unique, valuable book focusing on a single but immensely powerful human gene. It provides the first single source of comprehensive information on CYP2D6 that serves as an important reference for medical, biomedical, pharmaceutical, and nursing researchers, practitioners, and students.
Country of Publication:
30 September 2020
Introduction to Human Cytochrome P450 Superfamily. Mammalian CYP2D Members: A Comparison of Structure, Function, and Regulation. Substrates of Human CYP2D6. Inhibitors of Human CYP2D6. Regulation of Human CYP2D6. Structure and Function of Human CYP2D6. Clinical Pharmacogenomics of Human CYP2D6. General Discussion about Human CYP2D6.
Shufeng Zhou is the associate vice president of Global Medical Development and associate dean of international research in the College of Pharmacy of the University of South Florida in Tampa. He earned his PhD in pharmacology from the University of Auckland in New Zealand. His major research interests are systems pharmacology, drug metabolism and drug transport, pharmacokinetics/pharmacometrics, pharmacogenomics, nanomedicine, and Chinese medicine. He has published more than 450 peer-reviewed papers, 20 books and book chapters, and more than 440 conference abstracts. He was one of the Highly Cited Researchers of 2014 according to Thomson Reuter and has given more than 150 invited seminars and keynote presentations to academic institutions, government agencies, and high-profile international conferences. He serves as an editor or the editor in chief of at least 21 biomedical journals and is an editorial board member of more than 75 medical and pharmacological journals. He has received several national and international awards, is a voting member of US Pharmacopeia, a consultant for the World Health Organization and the Food and Drug Administration, and a council member or chair of several national and international professional societies.